Defining a role for c-Myc in breast tumorigenesis

Breast Cancer Research and Treatment

Volumn 44, Issue 1, 1997, Pages 1-22

  Nass, Sharyl J ^a   Dickson, Robert B ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Amplification; Apoptosis; Breast neoplasia; c Myc; Cell cycle; Overexpression

Indexed keywords

APOPTOSIS; BREAST CANCER; BREAST CARCINOGENESIS; CANCER THERAPY; CELL DEATH; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; HUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; REVIEW;

APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PROTO-ONCOGENE PROTEINS C-MYC;

EID: 0030966691     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1005858611585     Document Type: Review

References (178)

1. Ryan KM, Birnie GD: Myc oncogenes: the enigmatic family. Biochem J 314:713-721, 1996
2. Marcu KB, Bossone SA, Patel AJ: Myc function and regulation. Annu Rev Biochem 61:809-850, 1992
3. Spencer CA, Groudine M: Control of c-myc regulation in normal and neoplastic cells. Adv Cancer Res 56:1-48, 1991
4. Kato GJ, Dang CV: Function of the c-Myc oncoprotein. FASEB J 6:3065-3072, 1992
5. Meichle A, Philipp A, Eilers M: The functions of the Myc proteins. Biochim Biophys Acta 1114:129-146, 1992
6. Roy AL, Carruthers C, Gutjahr R, Roeder RG: Direct role for Myc in transcription initiation mediated by interactions with TFII-I. Nature 365:359-361, 1993
7. Lee LA, Dolde C, Barrett J, Wu CS, Dang CV: A link between c-myc-mediated transcriptional repression and neoplastic transformation. J Clin Invest 97:1687-1695, 1996
8. Amati B, Land H: Myc-Max-Mad: a transcription factor network controlling cell cycle progression, differentiation and death. Curr Opin Genet Dev 4:102-108, 1994
9. Eisenman RN: Myc, Max, and Mad: A regulatory network. Adv Oncol 10:3-6, 1994
10. Hurlin PJ, Queva C, Koskinen P, Steingrimsson E, Ayer DE, Copeland NG, Jenkins NA, Eisenman RN: Mad3 and Mad4: novel Max-interacting transcriptional repressors that suppress c-myc dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 14:5646-5659, 1995
11. Ayer DE, Lawrence QA, Eisenman RN: Mad-Max transcriptional repression is mediated by ternary complex formation with mammalian homologs of yeast repressor Sin3. Cell 80:767-776, 1995
12. Schreiber-Agus N, Chin L, Chen K, Torres R, Rao G, Guida P, Skoultchi AI, DePinho RA: An amino-terminal domain of Mxi1 mediates anti-Myc oncogenic activity and interacts with a homolog of the yeast transcriptional repressor SIN3. Cell 80:777-786, 1995
13. Hurlin PJ, Foley KP, Ayer DE, Hanahan D, Eisenman RN, Arbeit JA: Regulation of c-Myc and Mad during epidermal differentiation and HPV-associated tumorigenesis. Oncogene 11:2487-2501, 1995
14. Gandarillas A, Watt FW: Changes in expression of members of the fos and jun families and myc network during terminal differentiation of human keratinocytes. Oncogene 11:1403-1407, 1995
15. Larsson LG, Pettersson M, Oberg F, Nilsson K, Luscher B: Expression of mad, mxi1, max, and c-myc during induced differentiation of hematopoietic cells: opposite regulation of mad and c-myc. Oncogene 9:1247-1252, 1994
16. Ayer DE, Eisenman RN: A switch from Myc:Max to Mad:Max heterocomplexes accompanies monocyte/macrophage differentiation. Genes Dev 7:2110-2119, 1993
17. Zervos AS, Gyuris J, Brent R: Mxi1, a protein that specifically interacts with Max to bind Myc-Max recognition sites. Cell 72:223-232, 1993
18. Packham G, Cleveland JL: c-Myc and apoptosis. Biochim Biophys Acta 1242:11-28, 1995
19. Miltenberger RJ, Sukow KA, Farnham PJ: An E-box-mediated increase in cad transcription at the G1/S-phase boundary is suppressed by inhibitory c-Myc mutants. Mol Cell Biol 15:2527-2535, 1995
20. Galaktionov K, Chen X, Beach D: Cdc25 cell-cycle phosphatase as a target of c-myc. Nature 382:511-517, 1996
21. Seth A, Gupta S, Davis RJ: Cell cycle regulation of the c-myc transcriptional activation domain. Mol Cell Biol 13:4125-4136, 1993
22. Adnane J, Robbins PD: The retinoblastoma susceptibility gene product regulates Myc-mediated transcription. Oncogene 10:381-387, 1995
23. Gu W, Bhatia K, Magrath IT, Dang CV, Dalla-Favera R: Binding and suppression of the Myc transcriptional activation domain by p107. Science 264:251-254, 1994
24. Beijersbergen RL, Hijmans EM, Zhu L, Bernards R: Interaction of c-Myc with the pRb-related protein p107 results in inhibition of c-Myc-mediated transactivation. EMBO J 13:4080-4086, 1994
25. Meikrantz W, Schlegel R: Apoptosis and the cell cycle. J Cell Biochem 58:160-174, 1995
26. Barone MV, Courtneidge SA: Myc but not fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature 378:509-512, 1995
27. Eisenman RN, Cooper JA: Beating a path to Myc. Nature 378:438-439, 1995
28. Muthuswamy SK, Muller WJ: Direct and specific interaction of c-Src with Neu is involved in signaling by the epidermal growth factor receptor. Oncogene 11:271-279, 1995
29. Muthuswamy SK, Siegel PM, Dankort DL, Webster MA, Muller WJ: Mammary tumors expressing the neu proto-oncogene possess elevated c-Src tyrosine kinase activity. Mol Cell Biol 14:735-743, 1994
30. Mudryj M, Hiebert SW, Nevins JN: A role for the adenovirus inducible E2F transcription factor in a proliferation dependent signal transduction pathway. EMBO J 9:2179-2184, 1990
31. Roussel MF, Davis JN, Cleveland JL, Ghysdael J, Hiebert SW: Dual control of myc expression through a single DNA binding site targeted by ets family and E2F-1. Oncogene 9:405-415, 1994
32. Riggs KJ, Saleque S, Wong KK, Merrell KT, Lee JS, Shi Y, Calame K: Yin-Yang 1 activates the c-myc promoter. Mol Cell Biol 13:7487-7495, 1993
33. La Rosa FA, Pierce JW, Sonenshein GE: Differential regulation of the c-myc oncogene promotor by the NF-κB rel family of transcription factors. Mol Cell Biol 14:1039-1044, 1994
34. Marti A, Feng Z, Jehn B, Djonov V, Chicaiza G, Altermatt HJ, Jaggi R: Expression and activity of cell cycle regulators during proliferation and programmed cell death in the mammary gland. Cell Death Diff 2:227-283, 1995
35. Strange R, Li F, Saurer S, Burkhardt A, Frilis RR: Apoptotic cell death and tissue remodeling during mouse mammary gland involution. Development 115:49-68, 1992
36. Dubik D, Dembinski TC, Shiu RPC: Stimulation of c-myc oncogene expression associated with estrogen-induced proliferation of human breast cancer cells. Cancer Res 47:6517-6521, 1987
37. van der Burg B, van Selm-Miltenburg AJP, de Laat SW, van Zoelen EJJ: Direct effects of estrogen on c-fos and c-myc protooncogene expression and cellular proliferation in human breast cancer cells. Mol Cell Endo 64:223-228, 1989
38. Wosikowski K, Eppenberger U, Kung W, Nagamine Y, Mueller H: c-fos, c-jun and c-myc expressions are not growth rate limiting for the human MCF-7 breast cancer cells. Biochem Biophys Res Commun 188: 1067-1076, 1992
39. Davidson NE, Prestigiacomo LJ, Hahm HA: Induction of jun gene family members by transforming growth factor α but not 17β-estradiol in human breast cancer cells. Cancer Res 53:291-297, 1993
40. Leygue E, Gol-Winkler R, Compel A, Louis-Sylvestre C, Soquet L, Staub S, Kuttenn F, Mauvais-Jarvis P: Estradiol stimulates c-myc proto-oncogene expression in normal human breast epithelial cells in culture. J Steroid Biochem Molec Biol 52:299-305, 1995
41. Earashi M, Endo Y, Obata T, Minami M, Noguchi M, Miyazaki I, Sasaki T: Effects of linoleic acid and eicosanoid synthesis inhibitors on the growth and c-myc oncogene expression of human breast cancer cells. Int J Oncol 8:145-151, 1996
42. Fernandez-Pol JA, Talkad VD, Klos DJ, Hamilton PD: Suppression of the EGF-dependent induction of c-myc proto-oncogene expression by transforming growth factor beta in a human breast carcinoma cell line. Biochem Biophys Res Commun 144:1197-1205, 1987
43. Wilcken NRC, Sarcevic B, Musgrove EA, Sutherland RL: Differential effects of retinoids and antiestrogens on cell cycle progression and cell cycle regulatory genes in human breast cancer cells. Cell Growth Diff 7:65-74, 1996
44. Vink-van Wijngaarden T, Pols HAP, Buurman CJ, van den Bemd GJCM, Dorssers LCJ, Birkenhager JC, van Leewen JPTM: Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Res 54:5711-5717, 1994
45. Musgrove EA, Hamilton JA, Lee CSL, Sweeney KJE, Watts CKW, Sutherland RL: Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 13:3577-3587, 1993
46. Musgrove EA, Lee CSL, Sutherland RL: Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol 11: 5032-5043, 1991
47. Wong MSJ, Murphy LC: Differential regulation of c-myc by progestins and antiestrogens in T-47D human breast cancer cells. J Steroid Biochem Mol Biol 39:39-44, 1991
48. Le Roy X, Escot C, Brouillet JP, Theillet C, Maudelonde T, Simony-Lafontaine J, Pujol H, Rochefort H: Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer. Oncogene 6: 431-437, 1991
49. Eppenberger U, Wosikowski K, Kung W: Pharmacologic and biologic properties of Droloxifene, a new antiestrogen. Am J Clin Oncol 14:S5-S14, 1991
50. Wosikowski K, Kung W, Hasmann M, Loser R, Eppenberger U: Inhibition of growth-factor-activated proliferation by anti-estrogens and effects on early gene expression of MCF-7 cells. Int J Cancer 53: 290-297, 1993
51. Dubik D, Shiu RPC: Mechanism of estrogen activation of c-myc oncogene expression. Oncogene 7: 1587-1594, 1992
52. Reddel RR, Murphy LC, Hall RE, Sutherland RL: Differential sensitivity of human breast cancer cell lines to the growth-inhibitory effects of tamoxifen. Cancer Res 45:1525-1531, 1985
53. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN: Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol 13:513-529, 1995
54. Vignon F, Bouton MM, Rochefort H: Antiestrogens inhibit the mitogenic effect of growth factors on breast cancer cells in the total absence of estrogens. Biochem Biophys Res Commun 146:1502-1508, 1987
55. Kang Y, Cortina R, Perry RR: Role of c-myc in tamoxifen-induced apoptosis in estrogen-independent breast cancer cells. JNCI 88:279-284, 1996
56. Shiu RP, Watson PH, Dubik D: c-myc oncogene expression in estrogen-dependent and -independent breast cancer. Clin Chem 39:353-355, 1993
57. Dubik D, Shiu RPC: Transcriptional regulation of c-myc oncogene expression by estrogen in hormone-responsive human breast cancer cells. J Biol Chem 263:12705-12708, 1988
58. Miller TL, Jin Y, Sun JM, Coutts AS, Murphy LC, Davie JR: Analysis of human breast cancer nuclear proteins binding to the promoter elements of the c-myc gene. J Cell Biochem 60:560-571, 1996
59. Miller TL, Huzel NJ, Davie JR, Murphy LC: C-myc gene chromatin of estrogen receptor positive and negative breast cancer cells. Mol Cell Endocrinol 91:83-89, 1993
60. Watson PH, Pon RT, Shiu RPC: Inhibition of c-myc expression by phosphorothioate antisense oligonucleotide identifies a critical role for c-myc in the growth of human breast cancer. Cancer Res 51:3996-4000, 1991
61. Thomas TJ, Faaland CA, Gallo MA, Thomas T: Suppression of c-myc oncogene expression by a polyamine-complexed triplex-forming oligonucleotide in MCF-7 breast cancer cells. Nucl Acid Res 23: 3594-3599, 1995
62. Ray RB, Steele R, Seftor E, Hendrix M: Human breast carcinoma cells transfected with the gene encoding a c-myc promoter-binding protein (MBP-1) inhibits tumors in nude mice. Cancer Res 55: 3747-3751, 1995
63. Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FKH, Gewirtz DA: Growth arrest and non-apoptotic cell death associated with the suppression of c-Myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol 51:931-940, 1996
64. Fornari FA, Jarvis WD, Grant S, Orr MS, Randolph JK, White FKH, Mumaw VR, Lovings ET, Freeman RH, Gewirtz DA: Induction of differentiation and growth arrest associated with nascent (nonoligosomal) DNA fragmentation and reduced c-myc expression in MCF-7 human breast tumor cells after continuous exposure to a sublethal concentration of doxorubicin. Cell Growth Diff 5:723-733, 1994
65. Bunch RT, Povirk LF, Orr MS, Randolph JK, Fornari FA, Gewirtz DA: Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells. Biochem Pharmacol 47:317-329, 1994
66. Gewirtz DA, Fornari FA, Orr M, Randolph JK, Povirk L, Bunch RT: Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line: evidence for induction of gene-specific damage and alterations in gene expression. Cancer Res 53: 3547-3554, 1993
67. Orr MS, Fornari FA, Randolph JK, Gewirtz DA: Transcriptional down-regulation of c-myc expression in the MCF-7 breast tumor cell line by the topoisomerase II inhibitor, VM-26. Biochim Biophys Acta 1262:139-145, 1995
68. Levy N, Yonish-Rouach E, Oren M, Kimchi A: Complementation by wild-type p53 of interleukin-6 effects on M1 cells: Induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol 13:7942-7952, 1993
69. Hoang AT, Lutterbach B, Lewis BC, Yano T, Chou TY, Barrett JF, Raffeld M, Hann SR, Dang, CV: A link between increased transforming activity of lymphoma-derived MYC mutant alleles, their defective regulation by p107, and altered phosphorylation of the c-Myc transactivation domain. Mol Cell Biol 15:4031-4032, 1995
70. Escot C, Theillet C, Lidereau R, Spyratos F, Champeme MH, Gest J, Callahan R: Genetic alteration of the c-myc protooncogene (MYC) in human primary breast carcinomas. Proc Natl Acad Sci USA 83:4834-4838, 1986
71. Cline MJ, Battifora H, Yokota J: Proto-oncogene abnormalities in human breast cancer. Correlation with anatomic features and clinical course of disease. J Clin Oncol 5:999-1006, 1987
72. Varley JM, Swallow JE, Brammar WJ, Whittaker JL, Walker RA: Alterations to either c-erbB-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis. Oncogene 1:423-430, 1987
73. Bonilla M, Ramirez M, Lopez-Cueto J, Gariglio P: In vivo amplification and rearrangement of c-myc oncogene in human breast tumors. J Natl Cancer Inst 80:665-671, 1988
74. Guerin M, Barrois M, Terrier MJ, Spielmann M, Riou G: Overexpression of either c-myc or c-erbB-2/neu proto-oncogenes in human breast carcinomas: correlation with poor prognosis. Oncogene Res 3:21-31, 1988
75. Adnane J, Gaudray P, Simon MP, Simony-Lafontaine J, Jeanteur P, Theillet C: Proto-oncogene amplification and human breast tumor phenotype. Oncogene 4:1389-1395, 1989
76. Garcia I, Dietrich PY, Aapro M, Vauthier G, Vadas L, Engel F: Genetic alteration of c-myc, c-erbB-2 and c-Ha-ras protooncogenes and clinical associations in human breast carcinomas. Cancer Res 49:6675-6679, 1989
77. Tavassoli M, Quirke P, Farzaneh F, Lock NJ, Mayne LV, Kirkham N: C-erbB-2/c-erbA coamplification indicative of lymph node metastasis, and c-myc amplification of high tumor grade, in human breast carcinoma. Br J Cancer 60:505-510, 1989
78. Tsuda H, Hirahashi S, Shimosato Y, Hirota T, Tsugane S, Yamamoto H, Miyajima N, Toyoshima K, Yamamoto T, Yokota J, Yoshida T, Sakamura H, Terada M, Sugimura T: Correlation between long-term survival in breast cancer patients and amplification of two putative oncogene-coamplification units: hst-1/int-2 and c-erbB-2/ear-1. Cancer Res 49:3104-3108, 1989
79. Zhou DJ, Ahuja H, Cline MJ: Proto-oncogene abnormalities in human breast cancer: c-erbB-2 amplification does not correlate with recurrence of disease. Oncogene 4:105-108, 1989
80. Brouillet JP, Theillet C, Maudelonde T, Defrenne A, Simony-Lafontaine J, Sertour J, Pujol H, Jeanteur P, Rochefort H: Cathepsin D assay in primary breast cancer and lymph nodes: Relationship with c-myc, c-erb-B-2, and int-2 oncogene amplification and node invasiveness. Eur J Cancer 26:437-441, 1990
81. Munzel P, Marx D, Kochel H, Schauer A, Bock KW: Genomic alterations of the c-myc proto-oncogene in relation to the overexpression of c-erbB2 and Ki-67 in human breast and cervix carcinomas. J Cancer Res Clin Oncol 117:603-607, 1991
82. Berns EMJJ, Klijn JGM, van Puten WLJ, van Staveren IL, Portengen H, Foekens JA: c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res 52:1107-1113, 1992
83. Berns EMJJ, Klijn JGM, van Staveren IL, Portengen H, Noordegraaf E, Foekens JA: Prevalence of amplification of the oncogenes c-myc, HER2/neu, and int-2 in one thousand human breast tumours: Correlation with steroid receptors. Eur J Cancer 28:697-700, 1992
84. Borg A, Baldetorp B, Ferno M, Olsson H, Sigurdsson H: c-myc is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer 51:687-691, 1992
85. Kreipe H, Fischer L, Felgner J, Heidorn K, Mettler L, Parwaresch R: Amplification of c-myc, but not c-erb-B2 is associated with high proliferative capacity in breast cancer. Cancer Res 53:1956-61, 1993
86. Watson PH, Safneck JR Lee K, Dubik D, Shiu RPC: Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. JNCI 85:902-907, 1993
87. Bieche I, Champeme MH, Lidereau R: A tumor suppressor gene on chromosome 1p32-pter controls the amplification of MYC family genes in breast cancer. Cancer Res 54:4274-4276, 1994
88. Contegiacomo A, Pizzi C, Demarchis L, Alimandi M, Delrio P, Dipalma E, Petrella G, Ottini L, French D, Frati L, Bianco AR: High cell kinetics is associated with amplification of the Int-2, Bcl-1, Myc and ErbB-2 proto-oncogenes and loss of heterozygosity at the DO locus in primary breast cancers. Int J Cancer 61:1-6, 1995
89. Lonn U, Lonn S, Nilsson B, Stenkvist B: Prognostic value of erb-B2 and myc amplification in breast cancer imprints. Cancer 75:2681-2687, 1995
90. Varley JM, Wainwright AM, Brammar WJ: An unusual alteration in c-myc in tissue from a primary breast carcinoma. Oncogene 1:431-438, 1987
91. Kozbor D, Croce CM: Amplification of the c-myc oncogene in one of five human breast carcinoma cell lines. Cancer Res 44:438-441, 1984
92. Callahan R, Campbell G: Mutations in human breast cancer: An overview. JNCI 81:1780-1786, 1989
93. Thor AD, Yandell DW: Molecular pathology of breast carcinoma. In: Harris JR, Lippman ME, Morrow M, Hellman S (eds) Diseases of the Breast. Lippincott-Raven, Philadelphia PA, 1996, pp 221-235
94. Mariani-Costantini R, Escot C, Theillet C, Gentile A, Merlino G, Lidereau R, Callahan R: In situ c-myc expression and genomic status of the c-myc locus in infiltrating ductal carcinomas of the breast. Cancer Res 48:199-205, 1988
95. Spandidos DA, Pintzas A, Kakkanas A, Yiagnisis M, Mahera H, Patra E, Agnantis NJ: Elevated expression of the myc gene in human benign and malignant breast lesions compared to normal tissue. Anticancer Res 7:1299-1304, 1987
96. Pavelic ZP, Steele P, Preisler HD: Evaluation of c-myc proto-oncogene in primary human breast carcinomas. Anticancer Res 11:1421-1428, 1991
97. Pavelic ZP, Pavelic K, Carter CP, Pavelic L: Heterogeneity of c-myc expression in histologically similar infiltrating ductal carcinomas of the breast. J Cancer Res Clin Oncol 118:16-22, 1992
98. Pavelic ZP, Pavelic L, Lower EE, Gapany S, Barker EA, Preisler HD: c-myc, c-erbB-2, and Ki-67 expression in normal breast tissue and in invasive and non invasive breast carcinoma. Cancer Res 52:2597-2602, 1992
99. Bland KI, Konstadoulakis MM, Vezeridis MP, Wanebo HJ: Oncogene protein co-expression: Value of Ha-ras, c-myc, c-fos, and p53 as prognostic discriminants for breast carcinoma. Ann Surg 221:706-720, 1995
100. Pietilainen T, Lipponen P, Aaltomaa S, Eskelinen M, Kosma VM, Syrjanen K: Expression of c-myc proteins in breast cancer as related to established prognostic factors and survival. Anticancer Res 15: 959-964, 1995
101. Spandidos DA, Field JK, Agnantis NJ, Evan GI, Moore JP: High levels of c-myc protein in human breast tumours determined by a sensitive ELISA technique. Anticancer Res 9:821-826, 1989
102. Mizukami Y, Nonomura A, Takizawa T, Noguchi M, Michigishi T, Nakamura S, Ishizaki T: N-Myc protein expression in human breast carcinoma - Prognostic implications. Anticancer Res 15:2899-2905, 1995
103. Lizard-Nacol S, Lidereau R, Collin F, Arnal M, Hahnel L, Roignot P, Cuisenier J, Guerrin J: Benign breast disease - Absence of genetic alterations at several loci implicated in breast cancer malignancy. Cancer Res 55:4416-4419, 1995
104. Katz E, Carter BJ: A mutant cell line derived from NIH/3T3 cells: two oncogenes required for in vitro transformation. J Natl Cancer Inst 77:909-914, 1986
105. Land H, Parada LF, Weinberg RA: Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature 304:596-602, 1983
106. Bissonnette RP, Echeverri F, Mahboubi A, Green DR: Apoptotic death induced by c-myc is inhibited by bcl-2. Nature 359:554-556, 1992
107. Fanidi A, Harrington EA, Evan GI: Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359:554-556, 1992
108. Strasser A, Harris AW, Bath ML, Cory S: Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331-333, 1990
109. Wagner AJ, Small MB, Hay N: Myc-mediated apoptosis is blocked by ectopic expression of Bcl-2. Mol Cell Biol 13:2432-2440, 1993
110. Khazaie K, Panayotou G, Aguzzi A, Samarut J, Gazzolo L, Jurdic P: EGF promotes in vivo tumorigenic growth of primary chicken embryo fibroblasts expressing v-myc and enhances in vitro transformation by the v-erbA oncogene. Oncogene 6:21-28, 1991
111. Stern DF, Roberts AB, Roche NS, Sporn MB, Weinberg RA: Differential responsiveness of myc- and ras-transfected cells to growth factors: Selective stimulation of myc-transfected cells by epidermal growth factor. Mol Cell Biol 6:870-877, 1986
112. Sorrentino V, Drozdoff V, McKinney MD, Zeitz L, Fleissner E: Potentiation of growth factor activity by exogenous c-myc expression. Proc Natl Acad Sci USA 83:8167-8171, 1986
113. Leof EB, Proper JA, Moses HL: Modulation of transforming growth factor type β action by activated ras and c-myc. Mol Cell Biol 7:2649-2652, 1987
114. Reiss M, Dibble CL, Narayanan R: Transcriptional activation of the c-myc proto-oncogene in murine keratinocytes enhances the response to epidermal growth factor. J Invest Dermatol 93:136-141, 1989
115. Valverius EM, Ciardiello F, Heldin NE, Blondel B, Merlino G, Smith G, Stampfer MR, Lippman ME, Dickson RB, Salomon DS: Stromal influences on transformation of human mammary epithelial cells overexpressing c-myc and SV40T. J Cell Physiol 145:207-216, 1990
116. Telang NT, Osborne MP, Sweterlitsch LA, Narayanan R: Neoplastic transformation of mouse mammary epithelial cells by deregulated myc expression. Cell Reg 1:863-872, 1990
117. Ball RK, Ziemiecki A, Schonenberger CA, Reichmann E, Redmond SMS, Groner B: V-myc alters the response of a cloned mouse mammary epithelial cell line to lactogenic hormones. Mol Endo 2:133-142, 1988
118. Nguyen HQ, Selvakumaran M, Liebermann DA, Hoffman B: Blocking c-Myc and Max expression inhibits proliferation and induces differentiation of normal and leukcmic myeloid cells. Oncogene 11: 2439-2444, 1995
119. Schoenenbcrger CA, Andres AC, Groner B, van der Valk M, Lemeur M, Gerlinger P: Targeted c-myc gene expression in mammary glands of transgenic mice induces mammary tumors with constitutive milk protein gene transcription. EMBO J 7:169-175, 1988
120. Stewart TA, Pattengale PK, Leder P: Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes. Cell 38: 627-637, 1984
121. Leder A, Pattengale PK, Kuo A, Stewart TA, Leder P: Consequences of widespread deregulation of the c-myc gene in transgenic mice: Multiple neoplasms and normal development. Cell 45:485-495, 1986
122. Edwards PA, Ward JL, Bradbury JM: Alteration of morphogenesis by the v-myc oncogene in transplants of mammary gland. Oncogene 2:407-412, 1988
123. Amundadottir LT, Johnson MD, Merlino G, Smith G, Dickson RB: Synergistic interaction of transforming growth factor α and c-myc in mouse mammary and salivary gland tumorigenesis. Cell Growth Diff 6: 737-748, 1995
124. Sandgren EP, Schroeder JA, Qui TH, Palmiter RD, Brinster RL, Lee DC: Inhibition of mammary gland involution is associated with TGFα- but not c-myc-induced tumorigenesis in transgenic mice. Cancer Res 55:3915-3927, 1995
125. Cardiff RD, Sinn E, Muller W, Leder P: Transgenic oncogenic mice: tumor phenotype predicts genotype. Am J Pathol 139:495-501, 1991
126. Andres AC, van der Valk MA, Schonenberger CA, Fluckiger F, LeMeur M, Gerlinger P, Groner B: Ha-ras and c-myc oncogene expression interferes with morphological and functional differentiation of mammary epithelial cells in single and double transgenic mice. Genes Dev 2:1486-1495, 1988
127. Sinn E, Muller W, Pattengale P, Tepler I, Wallace R, Leder P: Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: synergistic action of oncogenes in vivo. Cell 49:465-475, 1987
128. Thompson AM: p53 and breast cancer. The Breast 2:8-10, 1993
129. Wang Y, Ramqvist T, Szekely L, Axelson H, Klein G, Wiman KG: Reconstitution of wild-type p53 expression triggers apoptosis in a p53-negative v-myc retrovirus-induced T-cell lymphoma line. Cell Growth Differ 4:467-473, 1993
130. Hermeking H, Eick D: Mediation of c-myc-induced apoptosis by p53. Science 265:2091-2093, 1994
131. Wagner AJ, Kokontis JM, Hay N: Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21 waf1/cip1. Genes Dev 8:2817-2830, 1994
132. Saito Y, Ogawa K: Wild type p53 and c-myc cooperation in generating apoptosis of a rat hepatocellular carcinoma cell line (FAA-HTC1). Oncogene 11:1013-1018, 1995
133. Blyth K, Terry A, O'Hara M, Baxter EW, Campbell M, Stewart M, Donehower LA, Onions DE, Neil JC, Cameron ER: Overexpression of a human c-myc transgene and p53 null phenotype in murine thymic lymphomas: contrasting effects of homozygous and heterozygous p53 loss. Oncogene 10:1717-1723, 1995
134. Elson A, Deng C, Campos-Torres J, Donehower LA, Leder P: The MMTV/c-myc transgene and p53 null alleles collaborate to induce T-cell lymphomas, but not mammary carcinomas in transgenic mice. Oncogene 11:181-190, 1995
135. Li M, Hu J, Heermeier K, Hennighausen L, Furth PA: Apoptosis and remodeling of mammary gland tissue during involution proceeds through p53-independent pathways. Cell Growth Diff 7:13-20, 1996
136. Eilers M, Schirm S, Bishop MJ: The Myc protein activates transcription of the alpha-prothymosin gene. EMBO J 10:133-141, 1991
137. Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC: Induction of apoptosis in fibroblasts by c-myc protein. Cell 69:119-128, 1992
138. Hanson KD, Shichiri M, Follansbee MR, Sedivy JM: Effects of c-myc expression on cell cycle progression. Mol Cell Biol 14:5748-5755, 1994
139. Karn J, Watson JV, Lowe AD, Green SM, Vedeckis W: Regulation of cell cycle duration by c-myc levels. Oncogene 4:773-787, 1989
140. Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, Neckers LM: A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature 328:445-449, 1987
141. Prochownik EV, Kukowska J, Rodgers C: c-myc antisense transcripts accelerate differentiation and inhibit G1 progression in murine erythroleukemia cells. Mol Cell Biol 8:3683-3695, 1988
142. Jansen-Durr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, Wessbecher J, Draetta G, Eilers M: Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci USA 90:3685-368, 1993
143. Philipp A, Schneider A, Vasrik I, Finke K, Xiong Y, Beach D, Alitalo K, Eilers M: Repression of cyclin D1: a novel function of MYC. Mol Cell Biol 14: 4032-4043, 1994
144. Hoang AT, Cohen KJ, Barrett JF, Bergstrom DA, Dang CV: Participation of cyclin A in Myc-induced apoptosis. Proc Natl Acad Sci USA 91:6875-6879, 1994
145. Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LZ: Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene 9:3635-3645, 1994
146. Roussel MF, Thedoras AM, Pagano M, Sherr CJ: Rescue of defective mitogenic signaling by D-type cyclins. Proc Natl Acad Sci USA 92:6837-6841, 1995
147. Kim YH, Buchholz MA, Chrest FJ, Nordin AA: Upregulation of c-myc induces the gene expression of the murine homologues of p34cdc2 and cyclin-dependent kinase-2 in T lymphocytes. J Immunol 152:4328-4334, 1994
148. Born TL, Frost JA, Schonthal A, Prendergast GC, Feramisco JR: c-Myc cooperates with activated ras to induce the cdc2 promoter. Mol Cell Biol 14:5710-5718, 1994
149. Steiner P, Philipp A, Lukas J, Godden-Kent D, Pagano M, Mittnacht S, Bartek J, Eilers M: Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J 14: 4814-4826, 1995
150. Nass SJ, Dickson RB: Cell cycle regulation in mammary epithelial cells which overexpress c-myc. AACR Special Conference (Cancer: The Interface Between Basic and Applied Research), Baltimore, MD, 1995, (Abstract #B-27).
151. Stampfer MR, Bartley JC: Human mammary epithelial cells in culture: differentiation and transformation. In: Lippman ME, Dickson RB (eds) Breast Cancer: Cellular and Molecular Biology. Kluwer Academic Publishers, Boston MA, 1988, pp 1-24
152. Nass SJ: Dual effects of c-myc overexpression on the survival and growth of mammary epithelial cells. Ph.D. Thesis, Georgetown University, 1996.
153. Hengst L, Reed SI: Translational control of p27Kip1 accumulation during the cell cycle. Science 271: 1861-1864, 1996
154. Pagano M, Tam SW, Theodoras AM, Beer-Romero P, Del Sal G, Chau V, Yew PR, Draetta GF, Rolfe M: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269:682-685, 1995
155. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM: Wild-type p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948, 1992
156. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD: Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 70:923-935, 1992
157. Chen J, Willingham T, Shuford, Nisen PD: Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. J Clin Invest 97:1983-1988, 1996
158. Mai S, Fluri M, Siwarski D, Huppi K: Genomic instability in MycER-activated Rat1a cells. Chromosom Res 4:365-371, 1996
159. Canman CE, Kastan MB: Induction of apoptosis by tumor suppressor genes and oncogenes. Sem Cancer Biol 6:17-25, 1995
160. Milner AE, Grand RJA, Waters CM, Gregory CD: Apoptosis in Burkitt lymphoma cells is driven by c-myc. Oncogene 8:3385-3391, 1993
161. Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR: Role for c-myc in activation-induced apoptotic cell death in T cell hybridomas. Science 257:212-214, 1992
162. Askew DS, Ashmun RA, Simmons BC, Cleveland JL: Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 6:1915-1922, 1991
163. Harrington EA, Bennett MR, Fanidi A, Evan GI: c-Myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13:3286-3295, 1994
164. Shi L, Nishioka WK, Th'ng J, Bradbury EM, Litchfield DW, Greenberg AH: Premature p34cdc2 activation required for apoptosis. Science 263:1143-1145, 1994
165. Meikrantz W, Gisselbrecht S, Tam SW, Schlegel R: Activation of cyclin A-dependent protein kinases during apoptosis. Proc Natl Acad Sci USA 91:3754-3758, 1994
166. Rudolph B, Saffrich R, Zwicker J, Henglein B, Muller R, Ansorge W, Eilers M: Activation of cyclin-dependent kinases by Myc mediates induction of cyclin, but not apoptosis. EMBO J 15:3065-3076, 1996
167. Packham G, Porter CW, Cleveland JL: c-Myc induces apoptosis and cell cycle progression by separable, yet overlapping, pathways. Oncogene 13: 461-496, 1996
168. Reisman D, Elkind NB, Roy B, Beamon J, Rotter V: c-Myc trans-activates the p53 promotor through a required downstream CACGTG motif. Cell Growth Differ 4:57-65, 1993
169. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293-299, 1995
170. Marin MC, Hsu B, Stephens LC, Brisbay S, McDonnell TJ: The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo. Exp Cell Res 217:240-247, 1995
171. Sakamuro D, Eviner V, Elliott KJ, Showe L, White E, Prendergast GC: c-Myc induces apoptosis in epithelial cells by both p53-dependent and p53-independent mechanisms. Oncogene 11:2411-2418, 1995
172. Hsu B, Marin MC, Elnaggar AK, Stephens LC, Brisbay S, Mcdonnell TJ: Evidence that c-Myc mediated apoptosis does not require wild-type p53 during lymphomagenesis. Oncogene 11:175-179, 1995
173. Gutierrez MI, Bhatia K, Siwarcki D, Wolff L, Magrath IT, Mushinski JF, Hupp K: Infrequent p53 mutation in mouse tumors with deregulated myc. Cancer Res 52:1032-1035, 1992
174. Lu X, Park SH, Thompson TC, Lane DP: Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70:153-161, 1992
175. Ryan JJ, Prochownik E, Gottlieb CA, Apel IJ, Merino R, Nunez G, Clarke MF: c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle. Proc Natl Acad Sci USA 91: 5878-5882, 1994
176. Levine AJ: The tumor suppressor genes. Ann Rev Biochem 62:623-651, 1993
177. Amundadottir LT, Nass SJ, Berchem G, Johnson MD, Dickson RB: Cooperation of TGFα and c-Myc in mouse mammary tumorigenesis: coordinated stimulation of growth and suppression of apoptosis. Oncogene 13:757-765, 1996
178. Nass SJ, Li M, Amundadottir LT, Furth PA, Dickson RB: Role for Bcl-xL in the regulation of apoptosis by EGF and TGFβ1 in c-Myc overexpressing mammary epithelial cells. Biochem Biophys Res Commun 227:248-256, 1996